Sentinel lymph node biopsy accurately assesses the axilla in 74% of locally advanced breast cancer patients who become clinically node negative after neoadjuvant chemotherapy, achieving a low false-negative rate of 2.1% with adequate mapping, according to findings published in the Journal of Clinical Oncology.
Clinical Accuracy and Trial Design in Advanced Breast Cancer
The prospective, multicenter trial led by Andrea V. Barrio and colleagues at Memorial Sloan Kettering Cancer Center evaluated 145 patients with locally advanced breast cancer—specifically clinical stage T4 and/or N2/N3 disease—who achieved a clinically node-negative status following neoadjuvant chemotherapy. Among the cohort, 44% presented with inflammatory breast cancer, 23% with other T4 disease, 12% with N2 disease, and 21% with N3 disease. All participants underwent sentinel lymph node biopsy utilizing dual-tracer mapping with technetium-99m sulfur colloid and isosulfan blue dye. This procedure was immediately followed by completion axillary lymph node dissection to definitively measure the diagnostic accuracy of the sentinel procedure.
Investigators defined adequate mapping as the retrieval of three or more sentinel lymph nodes, or the retrieval of one to two sentinel lymph nodes alongside the previously clipped metastatic node. Out of the 145 patients, researchers successfully identified at least one sentinel lymph node in 108 cases, representing a 74% overall identification rate. Detection rates varied across clinical presentations, registering numerically higher in patients presenting with advanced nodal disease at 83% to 87%, compared to those with T4 disease at 67% to 73%. Among the subset of 87 patients who achieved adequate mapping, 46% demonstrated a pathologic complete response in their lymph nodes.
Understanding the Sentinel Lymph Node Mapping Procedure
To safely evaluate whether cancer has spread beyond the primary tumor, surgeons utilize dual-tracer mapping—combining a radioactive tracer and a blue dye—to locate the first lymph nodes that receive lymphatic drainage from the breast. In the trial, researchers discovered that retrieving three or more nodes was achieved in 57% of patients overall. However, retrieval rates were notably lower in inflammatory and other T4 disease subsets, ranging from 45% to 55%, compared to 72% to 73% in advanced nodal disease cohorts.
When analyzing false-negative outcomes among the 47 patients with residual nodal disease and adequate mapping, only 1 patient had a false-negative result. This yielded a low false-negative rate of 2.1% with a 95% confidence interval of 0.1% to 12.7%. Conversely, among 21 patients who had only one to two sentinel nodes retrieved without a clipped metastatic node, the false-negative rate rose significantly to 22.2%, based on two false negatives among nine patients with residual disease.
Contraindications and When to Consult a Doctor
Despite the high pathologic complete response rate and low false-negative rate observed with adequate mapping, researchers caution that the study protocol required all patients to undergo completion axillary lymph node dissection. Consequently, the findings do not establish that it is safe to omit standard axillary lymph node dissection based solely on sentinel lymph node biopsy results. The data apply strictly to patients who became clinically node negative following neoadjuvant chemotherapy, and clinicians emphasize that these findings should not be extrapolated to individuals with persistent, clinically node-positive disease.
Patients undergoing breast cancer staging should consult their multidisciplinary oncology team regarding individualized surgical plans. Those with persistent clinical node positivity or individuals whose mapping procedures yield fewer than three nodes without a clipped metastatic node remain at higher risk for false-negative staging, making complete dissection the established standard of care.
Funding Sources and Global Context
The research received financial backing through grants from the National Institutes of Health and the National Cancer Institute Cancer Center Support Grant, alongside a faculty research award from the Memorial Sloan Kettering Cancer Department of Surgery. Several study authors disclosed financial relationships, including consulting fees, research support, and honoraria, with commercial entities such as Novartis, Merck, Takeda, and Boston Scientific.
Contextualizing global disease burdens and regional treatment standards, broader oncological data compiled by agencies such as the National Cancer Institute and published in journals like CA: A Cancer Journal for Clinicians underscore the critical need for precise staging tools to minimize surgical morbidity while maintaining oncological safety.
References
- Barrio AV, et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Journal of Clinical Oncology.
- Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026 Jan-Feb. 76 (1):e70043.
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun. 74 (3):229-263.
Disclaimer: This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
